Mitochondrial fusion promoter M1
Based on 2 publication(s) in Google Scholar
Mitochondrial fusion promoter M1 is a mitochondrial dynamic modulator. Mitochondrial fusion promoter M1 preserves the mitochondrial function and promotes cellular respiration. Mitochondrial fusion promoter M1 alleviates cardiac and brain damage in rats with cardiac ischemia/reperfusion injury.
For research use only. We do not sell to patients.
- Purity: 99.95%
- CAS No.: 219315-22-7
- Formula: C14H10Cl4N2O
- Molecular Weight:364.05
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Mitochondrial fusion promoter M1
More
Customer Validation & Images
-
IF
-
WB
Biological Activity
Mitochondrial fusion promoter M1 (5-25 μM; 24 h) promotes mitochondrial elongation in both Mitofusin-1 and Mitofusin -2 knock-out fibroblasts[2].
Mitochondrial fusion promoter M1 (20 μM; 12 h) decreases mito ROS to 1.0±0.44 fold, enhances mitochondrial membrane potential from 0.29±0.05 fold to 0.5±0.07 fold and restores mitochondrial architecture in BRIN-BD11 pancreatic beta cells[3].
Mitochondrial fusion promoter M1 (20 μM; 12 h) prevents the impairment of oxygen consumption rate in pancreatic beta cells due to cholesterol exposure[3].
Mitochondrial fusion promoter M1 (20 μM; 12 h) prevents the impairment of non-mitochondrial respiration and extracellular acidification rate (ECAR) in cholesterol enriched pancreatic beta cells[3].
Mitochondrial fusion promoter M1 (20 μM; 12 h) restores Glucose Stimulated Insulin Secretion (GSIS) in cholesterol treated pancreatic beta cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats (250-300g) receiving cardiac ischemia/reperfusion (I/R)[1]
-
Dosage:2 mg/kg
-
Administration:I.v. 15 minutes before cardiac I/R injury
-
Result:Increased brain mitochondrial fusion.
Increased blood-brain barrier (BBB) tight junction protein, and reduced macrophage infiltration in the brain.
Reduced brain mitochondrial dysfunction and apoptosis, but it did not reduce mitochondrial oxidative stress.
Reduced the expression of Alzheimer’s disease (AD)-related proteins.
Chemical Information
-
CAS No. 219315-22-7
-
Appearance Solid
-
Molecular Weight 364.05
-
Formula C14H10Cl4N2O
-
Color White to off-white
-
SMILES
C/C(C1=CC(Cl)=CC=C1O)=N\NC2=C(Cl)C=C(Cl)C=C2Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Ecotoxicol Environ Saf
Triphenyl phosphate induced apoptosis of mice testicular Leydig cells and TM3 cells through ROS-mediated mitochondrial fusion inhibition. [Abstract]2023 May:256:114876. PMID: 37027944
Mitochondrial fusion promoter M1 purchased from MedChemExpress. Usage Cited in: Ecotoxicol Environ Saf. 2023 May:256:114876. [Abstract]
Mitochondrial fusion promoter M1 (M1; 1 μM;12 h) significantly attenuates TPHP-induced mitochondrial reduction and abnormal alignment in TM3 cells.
Mitochondrial fusion promoter M1 purchased from MedChemExpress. Usage Cited in: Ecotoxicol Environ Saf. 2023 May:256:114876. [Abstract]
Mitochondrial fusion promoter M1 (M1; 1 μM;12 h) significantly increases the TPHP-induced expression of mitochondrial fusion proteins Mfn1, Mfn2 and Opa1 in TM3 cells.
-
Int Immunopharmacol
Mitochondrial calcium overload contributes to mechanical allodynia in neuropathic pain via inducing mitochondrial dynamic imbalance. [Abstract]2025 Jun 17:158:114863. PMID: 40359888
Solvent & Solubility
DMSO : 38.89 mg/mL (106.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 0.5 mg/mL (1.37 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 0.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 0.5 mg/mL (1.37 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 0.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Surinkaew P, et, al. Mitochondrial Fusion Promoter Alleviates Brain Damage in Rats with Cardiac Ischemia/Reperfusion Injury. J Alzheimers Dis. 2020;77(3):993-1003. [Content Brief]
[2]. Wang D, et, al. A small molecule promotes mitochondrial fusion in mammalian cells. Angew Chem Int Ed Engl. 2012 Sep 10;51(37):9302-5. [Content Brief]
[3]. Asalla S, et, al. Restoring Mitochondrial Function: A Small Molecule-mediated Approach to Enhance Glucose Stimulated Insulin Secretion in Cholesterol Accumulated Pancreatic beta cells. Sci Rep. 2016 Jun 10;6:27513. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7469 mL | 13.7344 mL | 27.4688 mL | 68.6719 mL |
| 5 mM | 0.5494 mL | 2.7469 mL | 5.4938 mL | 13.7344 mL | |
| 10 mM | 0.2747 mL | 1.3734 mL | 2.7469 mL | 6.8672 mL | |
| 15 mM | 0.1831 mL | 0.9156 mL | 1.8313 mL | 4.5781 mL | |
| 20 mM | 0.1373 mL | 0.6867 mL | 1.3734 mL | 3.4336 mL | |
| 25 mM | 0.1099 mL | 0.5494 mL | 1.0988 mL | 2.7469 mL | |
| 30 mM | 0.0916 mL | 0.4578 mL | 0.9156 mL | 2.2891 mL | |
| 40 mM | 0.0687 mL | 0.3434 mL | 0.6867 mL | 1.7168 mL | |
| 50 mM | 0.0549 mL | 0.2747 mL | 0.5494 mL | 1.3734 mL | |
| 60 mM | 0.0458 mL | 0.2289 mL | 0.4578 mL | 1.1445 mL | |
| 80 mM | 0.0343 mL | 0.1717 mL | 0.3434 mL | 0.8584 mL | |
| 100 mM | 0.0275 mL | 0.1373 mL | 0.2747 mL | 0.6867 mL |
Mitochondrial fusion promoter M1 Related Classifications
HY-111475 Related Classifications
Powered by Bioz